TABLE 3.
Results of phase randomization surrogate analyses for cardiorespiratory couplings between patients suffering from paranoid schizophrenia (SZO), healthy first-degree relatives (REL), and healthy control subjects (CON).
Index | CON vs. SZO | CON vs. REL | SZO vs. REL |
CON |
REL |
SZO |
|||||||
Median | [25–75] | Median | [25–75] | Median | [25–75] | ||||||||
Couplings | NF | *** | n.s | *** | −2.0 | −2.0 | −1.8 | −1.8 | −1.9 | −1.5 | −0.9 | −1.5 | −0.2 |
ABBI → RESP | *** | * | n.s | 0.03 | 0.02 | 0.04 | 0.05 | 0.04 | 0.06 | 0.06 | 0.04 | 0.07 | |
ARESP → BBI | *** | n.s | *** | 0.34 | 0.24 | 0.40 | 0.26 | 0.21 | 0.33 | 0.14 | 0.09 | 0.21 | |
MuTEBBI → RESP | ** | n.s | n.s | 0.002 | 0.000 | 0.008 | 0.005 | 0.002 | 0.012 | 0.008 | 0.003 | 0.016 | |
MuTERESP → BBI | n.s | n.s | n.s | 0.004 | 0.002 | 0.006 | 0.006 | 0.003 | 0.008 | 0.007 | 0.004 | 0.011 |
BB, beat-to-beat intervals; RESP, time intervals between consecutive breathing cycles; A, area from NSTPDC for identifying the coupling strength; MuTE, multivariate Transfer Entropy; p, univariate significance level: *<0.05, **<0.01, ***<0.004; n.s., not significant.